Friday, January 25, 2013

3200% premium for innovation!!

›
April 2012 Discussion posted on Pharmaceutical Discussion Group on Linkedin http://www.linkedin.com/groups/PhRMA-says-price-as-trig...

Why won't Gates spend a few more cents (per dose) on non-mercury biocides & shut-up the vaccine detractors?

›
April 2012 Discussion posted on Pharmaceutical Discussion Group on LI - by Murali Apparaju http://www.linkedin.com/groups/Why-wont-G...
1 comment:
Thursday, January 24, 2013

Review of Mahendra Ramsinghani's "The Business of Venture Capital: Insights from Leading Practitioners on the Art of Raising a Fund, Deal Structuring, Value Creation, and Exit Strategies

›
21 Aug 2012 Review Posted on Amazon.com http://www.amazon.com/review/R2Q6WI836ZOCJT/ref=cm_cr_pr_perm?ie=UTF8&ASIN=0470874449&li...

The clinical attrition of INX-189 post a 2.5 billion acquisition - are investors into life sciences really looking at where the buck is headed?

›
October 2012 Discussion initiated on Global Private Equity & Venture Capital  group on Linkedin http://www.linkedin.com/groupItem?vi...
1 comment:

Is the LP bias against investment into life-sciences contra-logical?

›
17 January 2013 Early Stage Biotech Showing Positive Signs of Scaling Its Wall of Worry by Bruce Booth on Forbes http://www.fo...
1 comment:

INX-189 clinical attrition - a call for re-look at single isomer strategy of Gilead?

›
October 2012 Discussion posted Pharmaceutical Discussion Group on LinkedIn http://www.linkedin.com/groups/INX-189-clinical-attrition...

The quintessential 'Indian vegetarian meal' prototype on Emirates

›
23 Nov 2012 On FB McKinsey article "the trouble with Travel distribution"  http://www.facebook.com/mckinseyquarterly/posts/43...
1 comment: